



Lupin announces Executive Board Leadership Changes

Mumbai, May 8, 2013: The Board of Directors, Lupin Limited announced changes at the Executive Board Level today. The Board of Directors approved the appointment of:

- Dr. Kamal K. Sharma as Vice Chairman
- Ms. Vinita Gupta as Chief Executive Officer, and
- Mr. Nilesh Gupta as the Managing Director

with effect from 1st September, 2013; subject to necessary approvals.

Commenting on the changes, Dr. D B Gupta, Founder and Chairman, Lupin Limited said “We have a very strong management team that has contributed to the dynamic growth of the company. We are now planning changes to prepare for the future that would take the company into higher orbits of growth. Kamal has very effectively led our team. As Vice Chairman, he would join me in setting the vision, building the strategy and mentoring the management team. Vinita has very effectively built Lupin’s presence in our largest market, the US and Nilesh has ably led the company’s research and supply chain functions. I expect both of them in the capacity of CEO and MD respectively to now effectively lead the company.”

About Lupin Limited

Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.

Lupin is the 5th largest and fastest growing top 5 generics player in the US (5.3% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).

Press Release



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

For the financial year ended March 2013, Lupin's Consolidated turnover and Profit after Tax were Rs. 94,616 million (USD 1.74 billion) and Rs. 13,142 million (USD 242 million) respectively. Please visit <http://www.lupinworld.com> for more information.

For further information or queries please contact -

Shamsher Gorawara
Head – Corporate Communications
Lupin Limited:
Ph: +91 98 20 338 555
Email: shamshergorawara@lupinpharma.com

or

Rajiv Pillai
Head – Investor Relations
Lupin Limited:
Ph: +91 98 20 552 083
Email: rajivpillai@lupinpharma.com